Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2‘-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics-Reference-Cited by-同舟云学术

Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2‘-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics

Published:2004-12-15 Issue:1 Volume:48 Page:171-179
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Murugesan Natesan¹,Gu Zhengxiang¹,Fadnis Leena¹,Tellew John E.¹,Baska Rose Ann F.¹,Yang Yifan¹,Beyer Sophie M.¹,Monshizadegan Hossain¹,Dickinson Kenneth E.¹,Valentine Maria T.¹,Humphreys W. Griffith¹,Lan Shih-Jung¹,Ewing William R.¹,Carlson Kenneth E.¹,Kowala Mark C.¹,Zahler Robert¹,Macor John E.¹

Affiliation:

1. Discovery Chemistry and Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-5400

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm049548x

Reference26 articles.

1. The Heterogeneity of Hypertension: Why Doesn't Every Patient Respond to Every Antihypertensive Drug?

2. Single pericytes and pericytes in suspension are stimulated in a similar way by low-density lipoprotein

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and clinical application of new drugs approved by FDA in 2023;European Journal of Medicinal Chemistry;2024-02

2. Sparsentan — Another Arrow in the Quiver for Treatment of FSGS?;New England Journal of Medicine;2023-12-28

3. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis;New England Journal of Medicine;2023-12-28

4. Endothelin Receptor Antagonists in Kidney Disease;International Journal of Molecular Sciences;2023-02-08

5. What are the challenges with multi-targeted drug design for complex diseases?;Expert Opinion on Drug Discovery;2022-05-12